At the news
? BULLISHIMPACT 9/10 PRESS-RELEASE filed Mar 25, 2026 at 11:50 ET
Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic therapy designed to cross the blood-brain barrier for the treatment of neurologic manifestations of Hunter syndrome (MPS II). The approval is based on biomarker reduction in cerebrospinal fluid heparan sulfate, with a confirmatory Phase 2/3 trial ongoing. Denali also received a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the approval.
- FDA granted accelerated approval to AVLAYAH™ for neurologic manifestations of Hunter syndrome (MPS II), a rare lysosomal storage disease.
- AVLAYAH is the first FDA-approved therapy engineered to cross the blood-brain barrier via Denali’s TransportVehicle™ platform targeting the transferrin receptor.
- Approval based on 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) by week 24 in a Phase 1/2 trial, with 93% of patients reaching normal CSF HS levels.
- Denali received a Rare Pediatric Disease Priority Review Voucher (PRV), which can be sold or used to accelerate review of a future drug application.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access